Clinical Research Directory
Browse clinical research sites, groups, and studies.
Duchenne Electronic Health Record Study
Sponsor: The Duchenne Registry
Summary
This study aims to collect retrospective and prospective, long-term data of patients with dystrophinopathy (including Duchenne, Becker, and female carriers) through electronic transfer. At select clinics across the United States, electronic health record (EHR) data from consented patients will be pushed into PPMD's Duchenne Outcomes Research Interchange (the Interchange), where the EHR data can be combined with patient-reported data from The Duchenne Registry. By combining this data in a central hub, we will gain a more complete picture of Duchenne and Becker muscular dystrophy, allowing researchers and clinicians to develop treatments faster and to improve and refine the standards of care for Duchenne and Becker. The ultimate goal is to optimize function, quality of life, and survival of Duchenne and Becker patients. EHR data collected will be fully identifiable retrospective data for core clinical data elements going back ten years (as available) from the date of consent; going back one year for retrospective clinical notes from the date of consent; and prospectively collecting both core clinical data elements and clinical notes. Information collected will align with the FHIR U.S. core data elements, also known as the Common Clinical Data Set. PPMD partnered with Prometheus Research (an IQVIA company), an industry leader in health data informatics, to launch both the EHR Study and the Interchange. All data is stored securely and in accordance with strict industry standards and patient privacy laws. Participation in the EHR data extraction is voluntary, and a patient can withdraw consent at any time.
Official title: Duchenne Outcomes Research Interchange Data Enrichment Through EHR Extraction
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
2500
Start Date
2022-12-01
Completion Date
2072-12
Last Updated
2026-05-27
Healthy Volunteers
No
Conditions
Interventions
Observational study with patients who may be treated with various disease-modifying therapies
Patients may be on any combination of therapies to participate, including FDA-approved therapies (corticosteroids, exon skipping therapy, gene therapy) or therapies in clinical trial.
Locations (10)
Arkansas Children's Hospital
Little Rock, Arkansas, United States
UC Davis Health
Sacramento, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Yale Children's Hospital
New Haven, Connecticut, United States
Children's National Medical Center
Washington D.C., District of Columbia, United States
University of Iowa Health Care
Iowa City, Iowa, United States
Duke University Medical Center
Durham, North Carolina, United States
UT Southwestern Medical Center
Dallas, Texas, United States
Primary Children's Hospital
Salt Lake City, Utah, United States
University of Utah Health
Salt Lake City, Utah, United States